Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 5/2016

12.09.2016 | Original Article

Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumors

verfasst von: Martin J. Edelman, Rena Lapidus, Josephine Feliciano, Miroslav Styblo, Jan H. Beumer, Tao Liu, Jogarao Gobbru

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

KML-001 (sodium metaarsenite) displaces hTERT from the nucleus and is synergistic with cisplatin. This phase I trial tested the tolerability, activity and pharmacology of this combination.

Methods

Patients with advanced solid tumors that were “platinum sensitive,” PS 0-1, normal renal and hepatic function were eligible. Treatment was with cisplatin 75 mg/m2 day 1 and KML-001 p.o. daily days 1–14 on a 21-day cycle. A standard 3 + 3 design was employed. Blood specimens for arsenic and platinum pharmacokinetics were obtained at 0, 1, 2, 3, 4, 5, 6, 24 h and days 8, 15 and 22.

Results

Eighteen patients (7 M, 11 F) were evaluable for the primary endpoint of toxicity. Patients were heavily pretreated for a variety of malignancies (mean number of prior regimens = 3). Sixteen had prior platinum therapy. The dose-limiting toxicity was prolongation of the QTc interval, seen in three patients in cohort 3 (20 mg) (two during cycle 1, one during cycle 2). A documented response was seen in a patient with heavily pretreated SCLC in cohort one. Several other patients had reduction in tumor burden. In addition to the dose-limiting toxicity of QTc prolongation, the most common toxicities observed were nausea and vomiting and cytopenias. Myelosuppression was primarily seen in patients who had undergone prior radiotherapy.

Conclusions

The combination of KML-001 and cisplatin was technically feasible and active. However, the occurrence of significant QTc prolongation led to discontinuation of the trial. This prolongation was likely a result of electrolyte abnormalities resulting from cisplatin superimposed on the known risks of arsenicals and QTc prolongation. Combinations with other platinum agents (e.g., carboplatin) should be considered. This is the first fully reported human trial of KML-001.
Literatur
2.
Zurück zum Zitat Keith WN, Evans JTR, Glasspool RM (2001) Telomerase and cancer: time to move from a promising target to a clinical reality. J Pathol 195:404–414CrossRefPubMed Keith WN, Evans JTR, Glasspool RM (2001) Telomerase and cancer: time to move from a promising target to a clinical reality. J Pathol 195:404–414CrossRefPubMed
3.
Zurück zum Zitat Feng J, Funk WD, Wang SS et al (1995) The RNA component of human telomerase. Science 269:1236–1241CrossRefPubMed Feng J, Funk WD, Wang SS et al (1995) The RNA component of human telomerase. Science 269:1236–1241CrossRefPubMed
4.
Zurück zum Zitat Nakamura TM, Morin GB, Chapman KB et al (1997) Telomerase catalytic subunit homologs from fission yeast and human. Science 277:955–959CrossRefPubMed Nakamura TM, Morin GB, Chapman KB et al (1997) Telomerase catalytic subunit homologs from fission yeast and human. Science 277:955–959CrossRefPubMed
6.
Zurück zum Zitat Kim NW, Piatyszek MA, Prowse KR et al (1994) Specific association of human telomerase activity with immortal cells and cancer. Science 266:2011–2015CrossRefPubMed Kim NW, Piatyszek MA, Prowse KR et al (1994) Specific association of human telomerase activity with immortal cells and cancer. Science 266:2011–2015CrossRefPubMed
7.
Zurück zum Zitat Burger AM, Bibby MC, Double JA (1997) Telomerase activity in normal and malignant mammalian tissues: feasibility of telomerase as target for cancer chemotherapy. Br J Cancer 75:516–522CrossRefPubMedPubMedCentral Burger AM, Bibby MC, Double JA (1997) Telomerase activity in normal and malignant mammalian tissues: feasibility of telomerase as target for cancer chemotherapy. Br J Cancer 75:516–522CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Shay JW, Bacchetti S (1997) A survey of telomerase activity in human cancer. Eur J Cancer 33:787–791CrossRefPubMed Shay JW, Bacchetti S (1997) A survey of telomerase activity in human cancer. Eur J Cancer 33:787–791CrossRefPubMed
9.
Zurück zum Zitat Soignet SL, Frankel SR, Douer D et al (2001) United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 19:3852–3860PubMed Soignet SL, Frankel SR, Douer D et al (2001) United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 19:3852–3860PubMed
10.
Zurück zum Zitat Douer D, Tallman M (2005) Arsenic trioxide: a new clinical experience with an old medication in hematologic malignancies. J Clin Oncol 23:2396–2410CrossRefPubMed Douer D, Tallman M (2005) Arsenic trioxide: a new clinical experience with an old medication in hematologic malignancies. J Clin Oncol 23:2396–2410CrossRefPubMed
11.
Zurück zum Zitat Alamolhodaei NS, Shirani K, Karimi G (2015) Arsenic cardiotoxicity: an overview. Environ Toxicol Pharmacol 40:1005–1014CrossRefPubMed Alamolhodaei NS, Shirani K, Karimi G (2015) Arsenic cardiotoxicity: an overview. Environ Toxicol Pharmacol 40:1005–1014CrossRefPubMed
12.
Zurück zum Zitat Berenson JR, Boccia R, Siegel D et al (2006) Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study. Br J Haematol 135:174–183CrossRefPubMed Berenson JR, Boccia R, Siegel D et al (2006) Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study. Br J Haematol 135:174–183CrossRefPubMed
13.
Zurück zum Zitat Phatak P, Dai F, Butler M, Nandakumar MP, Gutierrez PL, Edelman MJ, Hendriks H, Burger AM (2008) KML001 cytotoxic activity is associated with its binding to telomeric sequences and telomere erosion in prostate cancer cells. Clin Cancer Res 14:4593–4602CrossRefPubMed Phatak P, Dai F, Butler M, Nandakumar MP, Gutierrez PL, Edelman MJ, Hendriks H, Burger AM (2008) KML001 cytotoxic activity is associated with its binding to telomeric sequences and telomere erosion in prostate cancer cells. Clin Cancer Res 14:4593–4602CrossRefPubMed
14.
Zurück zum Zitat Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27–55CrossRefPubMed Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27–55CrossRefPubMed
15.
Zurück zum Zitat Matoušek T, Hernández-Zavala A, Svoboda M, Langrová L, Adair BM, Drobná Z, Thomas DJ, Stýblo M, Dědina J (2008) Oxidation state specific generation of arsines from methylated arsenicals based on L-Cysteine treatment in buffered media for speciation analysis by hydride generation - automated cryotrapping - gas chromatography-atomic absorption spectrometry with the multiatomizer. Spectrochim Acta Part B At Spectrosc. 63:396–406CrossRefPubMedPubMedCentral Matoušek T, Hernández-Zavala A, Svoboda M, Langrová L, Adair BM, Drobná Z, Thomas DJ, Stýblo M, Dědina J (2008) Oxidation state specific generation of arsines from methylated arsenicals based on L-Cysteine treatment in buffered media for speciation analysis by hydride generation - automated cryotrapping - gas chromatography-atomic absorption spectrometry with the multiatomizer. Spectrochim Acta Part B At Spectrosc. 63:396–406CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Colville H, Dzadony R, Kemp R et al (2010) In vitro circuit stability of 5-fluorouracil and oxaliplatin in support of hyperthermic isolated hepatic perfusion. J Extra Corp Technol 42:75–79 Colville H, Dzadony R, Kemp R et al (2010) In vitro circuit stability of 5-fluorouracil and oxaliplatin in support of hyperthermic isolated hepatic perfusion. J Extra Corp Technol 42:75–79
17.
Zurück zum Zitat Zhang B, Suer S, Livak F et al (2012) Telomere and microtubule targeting in treatment-sensitive and treatment-resistant human prostate cancer cells. Mol Pharmacol 82:310–321CrossRefPubMed Zhang B, Suer S, Livak F et al (2012) Telomere and microtubule targeting in treatment-sensitive and treatment-resistant human prostate cancer cells. Mol Pharmacol 82:310–321CrossRefPubMed
18.
Zurück zum Zitat Yoon JS, Kim ES, Park BB et al (2015) Anti-leukemic effect of sodium metaarsenite (KML001) in acute myeloid leukemia with breaking-down the resistance of cytosine arabinoside. Int J Oncol 46:1953–1962PubMed Yoon JS, Kim ES, Park BB et al (2015) Anti-leukemic effect of sodium metaarsenite (KML001) in acute myeloid leukemia with breaking-down the resistance of cytosine arabinoside. Int J Oncol 46:1953–1962PubMed
19.
Zurück zum Zitat Moon CH, Lee SJ, Lee HY et al (2013) KML001 displays vascular disrupting properties and irinotecan combined antitumor activities in a murine tumor model. PLoS One 8:e53900CrossRefPubMedPubMedCentral Moon CH, Lee SJ, Lee HY et al (2013) KML001 displays vascular disrupting properties and irinotecan combined antitumor activities in a murine tumor model. PLoS One 8:e53900CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Woo SR, Ham Y, Kang W et al (2014) KML001, a telomere-targeting drug, sensitizes glioblastoma cells to temozolomide chemotherapy and radiotherapy through DNA damage and apoptosis. Biomed Res Int 2014:747415CrossRefPubMedPubMedCentral Woo SR, Ham Y, Kang W et al (2014) KML001, a telomere-targeting drug, sensitizes glioblastoma cells to temozolomide chemotherapy and radiotherapy through DNA damage and apoptosis. Biomed Res Int 2014:747415CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Yoon JS, Hwang DW, Kim ES et al (2016) Anti-tumoral effect of arsenic compound, sodium metaarsenite (KML001), in non-Hodgkin’s lymphoma: an in vitro and in vivo study. Invest New Drugs 34:1–14CrossRefPubMed Yoon JS, Hwang DW, Kim ES et al (2016) Anti-tumoral effect of arsenic compound, sodium metaarsenite (KML001), in non-Hodgkin’s lymphoma: an in vitro and in vivo study. Invest New Drugs 34:1–14CrossRefPubMed
22.
Zurück zum Zitat Urien S, Lokiec F (2004) Population pharmacokinetics of total and unbound plasma cisplatin in adult patients. Br J Clin Pharmacol 57(6):756–763CrossRefPubMedPubMedCentral Urien S, Lokiec F (2004) Population pharmacokinetics of total and unbound plasma cisplatin in adult patients. Br J Clin Pharmacol 57(6):756–763CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Urien S, Brain E, Bugat R et al (2005) Pharmacokinetics of platinum after oral or intravenous cisplatin: a phase 1 study in 32 adult patients. Cancer Chemother Pharmacol 55:55–60CrossRefPubMed Urien S, Brain E, Bugat R et al (2005) Pharmacokinetics of platinum after oral or intravenous cisplatin: a phase 1 study in 32 adult patients. Cancer Chemother Pharmacol 55:55–60CrossRefPubMed
24.
Zurück zum Zitat Lara PN, Redman MW, Kelly K et al (2008) Disease control rate at 8 weeks predicts clinical benefit in advanced non-small cell lung cancer: results from southwest oncology group randomized trials. J Clin Oncol 26:463–467CrossRefPubMed Lara PN, Redman MW, Kelly K et al (2008) Disease control rate at 8 weeks predicts clinical benefit in advanced non-small cell lung cancer: results from southwest oncology group randomized trials. J Clin Oncol 26:463–467CrossRefPubMed
Metadaten
Titel
Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumors
verfasst von
Martin J. Edelman
Rena Lapidus
Josephine Feliciano
Miroslav Styblo
Jan H. Beumer
Tao Liu
Jogarao Gobbru
Publikationsdatum
12.09.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 5/2016
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-016-3148-x

Weitere Artikel der Ausgabe 5/2016

Cancer Chemotherapy and Pharmacology 5/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.